Overview

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

Status:
Unknown status

Trial end date:
2020-03-31

Target enrollment:

Participant gender:

Summary

No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in venous thromboembolism across Danish hospitals.

Phase:

Phase 4

Details

Lead Sponsor:

Danish Heart Foundation

Collaborator:

Danish Society of Cardiology

Treatments:

Anticoagulants
Apixaban
Dabigatran
Edoxaban
Rivaroxaban